| Literature DB >> 35573250 |
Lisa Haueis1,2, Marlitt Stech1, Stefan Kubick1,3,4.
Abstract
Cell-free systems are well-established platforms for the rapid synthesis, screening, engineering and modification of all kinds of recombinant proteins ranging from membrane proteins to soluble proteins, enzymes and even toxins. Also within the antibody field the cell-free technology has gained considerable attention with respect to the clinical research pipeline including antibody discovery and production. Besides the classical full-length monoclonal antibodies (mAbs), so-called "nanobodies" (Nbs) have come into focus. A Nb is the smallest naturally-derived functional antibody fragment known and represents the variable domain (VHH, ∼15 kDa) of a camelid heavy-chain-only antibody (HCAb). Based on their nanoscale and their special structure, Nbs display striking advantages concerning their production, but also their characteristics as binders, such as high stability, diversity, improved tissue penetration and reaching of cavity-like epitopes. The classical way to produce Nbs depends on the use of living cells as production host. Though cell-based production is well-established, it is still time-consuming, laborious and hardly amenable for high-throughput applications. Here, we present for the first time to our knowledge the synthesis of functional Nbs in a standardized mammalian cell-free system based on Chinese hamster ovary (CHO) cell lysates. Cell-free reactions were shown to be time-efficient and easy-to-handle allowing for the "on demand" synthesis of Nbs. Taken together, we complement available methods and demonstrate a promising new system for Nb selection and validation.Entities:
Keywords: CHO cell lysate; In vitro transcription/translation; VHH; camelid; cell-free protein synthesis; nanobody
Year: 2022 PMID: 35573250 PMCID: PMC9096027 DOI: 10.3389/fbioe.2022.896763
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Graphical representation of different antibody structures and recombinantly expressible formats. (A) A conventional full length IgG antibody consists of two identical light (variable—VL and constant—CL domain) and two identical heavy polypeptide chains (variable VH and constant—CH1/2/3 domains) which assemble into a heterotetramer. Single chain variable fragments (scFv) are recombinant binders consisting of the variable domain of antibody heavy chain (VH) and antibody light chain (VL) fused by a flexible peptide linker. (B) A camelid heavy-chain-only antibody (HCAb) consists of two identical heavy polypeptide chains (variable—VHH and constant CH2/3 domains) forming a homodimer. The antigen binding region of HCAbs is called VHH domain or Nanobody. (C) Schematic view of the VHH domain consisting of 2 ß-sheets, one with 4 and one with 5 ß-strands. Scaffold ß strands are depicted in grey (A, B, E, D, C″, C′, C, F, G), antigen-binding loops in dark orange (CDR1), light orange (CDR2) and in red (CDR3). The frequently observed interloop disulfide bond betwenn CDR1 and CDR3 is depicted in green.
FIGURE 2Cell-free synthesis of anti-GFP-Nb and anti-EGFR-Nb based on CHO lysate. (A,B) Autoradiographs showing 14C-leucine labeled Nanobodies in both soluble fractions of the translation mixture (SN1, SN2). (C,D). Quantitative analysis of cell-free synthesized Nbs was performed by liquid scintillation counting. Standard deviations were calculated from quadruplicate analysis.
FIGURE 3ELISA analysis showing the specific binding of cell-free synthesized Nbs to their corresponding antigens. Nbs without signal sequence (NC) were analyzed in SN1 (comprising non-translocated Nbs). Nbs with signal sequence (NCM) were analyzed in SN1 and additionally in SN2 (comprising Nbs which were solubilized from the lumen of the endogenous CHO microsomes). No template control (NTC) and PBS were analyzed in parallel as negative controls. To monitor background binding Nb samples were also analyzed on wells coated without (w/o) antigen. (A,B) Binding of anti-GFP-Nb to its antigen green fluorescent protein (GFP) was analyzed in serial dilutions in the range of 34–1 nM. (C) Binding of anti-EGFR-Nb to epidermal growth factor receptor (EGFR) was analyzed in serial dilutions in the range of 2–0.1 nM. Standard deviations were calculated from quadruplicate analysis (A,B) and duplicate analysis (C).